Markets
Denali Stock Surges 7%, Adding $213 Million, After Hunter Syndrome Drug Sales Guidance
Shares rose after the biotech guided to much higher sales of its Hunter syndrome drug, though a voucher sale drove its profit.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Markets
Shares rose after the biotech guided to much higher sales of its Hunter syndrome drug, though a voucher sale drove its profit.
Markets
The lender posted third-quarter net income of $212.6 million, reversing a second-quarter loss, even as originations fell again.
Markets
The insurer's shares fell in Wednesday trading after a reinsurance-related investment loss and a 60.4% slide in group disability profit.
Markets
Shares added $228 million in value as Lumvoa's launch topped 100 patients by September's end.
Markets
Shares fell after third-quarter revenue declined, even as a second lease lifted expected AI contract value.
Markets
The thermal-management maker's adjusted earnings came in under the analyst average even as data center sales rose 95%.
Markets
The contractor posted record third-quarter earnings and lifted its full-year targets, yet its shares fell sharply the next session.
Markets
The bank-technology provider is putting debt reduction ahead of repurchases, and its CFO is leaving after a third quarter that grew 3.7% on a pro forma basis.
Markets
Clear Secure raised its annual free cash flow minimum to $490 million and expanded its share repurchase program by $175 million.
Markets
Shoals holders would own about 65% of the combined company, even as Array lowered its 2026 revenue forecast.
Markets
The language-learning app's user growth sped up and it raised its yearly forecast, even as profit margins narrowed.
Markets
Sanofi is terminating the oral STAT6 degrader program it shared with Nurix, though other licensed programs remain.